• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Fat Tail Daily

Investment Ideas From the Edge of the Bell Curve

  • Menu
    • Commodities
      • Resources and Mining
      • Copper
      • Gold
      • Iron Ore
      • Lithium
      • Silver
      • Graphite
      • Rare Earths
    • Technology
      • AI
      • Bitcoin
      • Cryptocurrency
      • Energy
      • Financial Technology
      • Bio Technology
    • Market Analysis
      • Latest ASX News
      • Dividend Shares
      • ETFs
      • Stocks and Bonds
    • Macro
      • Australian Economy
      • Central Banks
      • World Markets
    • Small Caps
    • More
      • Investment Guides
      • Premium Research
      • Editors
      • About
      • Contact Us
  • Latest
  • Fat Tail Series
  • About Us
Technology Bio Tech

Creso Pharma Secures New Win in Canada — Shares Up 8% (ASX:CPH)

Like 0

By Ryan Clarkson-Ledward, Wednesday, 11 August 2021

Aussie pot stock Creso Pharma [ASX:CPH] share price is on the up today. The share price is currently trading 8% higher at time of writing.

Aussie pot stock Creso Pharma Ltd [ASX:CPH] shares is on the up today.

The share price is currently trading 8% higher at time of writing. Climbing on the back of some positive news from one of Creso’s Canadian subsidiaries.

Let’s take a closer look…

New licence, new orders

Mernova, a wholly-owned subsidiary of Creso, has been granted approval for an extension of its cannabis sales licence. Giving the company the ability to sell medicinal products direct-to-patient without the need for a wholesaler.

This win is a big milestone for Mernova and Creso, opening the business up to the medicinal market for the first time.

On top of this, Mernova has secured some new purchase orders. Sales that not only testify to the quality of its product, but also the demand — with $242,546 worth of recent purchase orders according to Creso’s update.

And with ongoing product development still underway, these figures may just be the start of a broader trend. Particularly as Mernova devises its strategy for both medicinal and recreational customers.

Mernova’s managing director, Jack Yu, says:

‘Mernova is well positioned to expand its presence in the Canadian medicinal market, while continuing to increase market share in the country’s growing recreational market. The direct-to-patient medicinal market has the potential to be huge for us. It increases our distribution channels from four provinces and territories to nation-wide, and allows for direct-to-patient sales, which provides us with increased control over pricing, as well as direct interaction with, and feedback from, valued customers.

‘We anticipate this licence expansion to allow us to considerably grow our revenue profile and profit margins, and that the potential of a recurring revenue model for medicinal sales may also provide increased predictability and stability of cashflows, forecasts, and downstream supply chain management. Planning for our direct-to-patient medicinal launch is underway, and we look forward to supplying our top-quality product to patients, nation-wide.’

What’s next for the Creso Share Price?

Today’s development is a welcome one for investors. A clear sign that they’re buying into the growth and progress that Creso is making in the Canadian market.

With further ventures and plans in the North American nation, this is not the company’s only focus. Management has plenty of juggling to do between different interests.

For investors, it will be telling to see where Creso decides to devote most of its attention. Because with operations across recreational and medicinal cannabis, as well as psychedelics like psilocybin, the company may be biting off more than it can chew.

But if it succeeds Creso may just carve out a piece of three huge sectors in this emerging market. Time will tell…

And if you’re looking for more pot stock tips or ideas, then check out our latest report. We’ve rounded up three top cannabis-related plays to light a fire under your potential returns. Check them out, for free, in our full report, right here.

Regards,

Ryan Clarkson-Ledward,
For Money Morning

PS: Our publication Money Morning is a fantastic place to start on your investment journey. We talk about the big trends driving the most innovative stocks on the ASX. Learn all about it here

All advice is general advice and has not taken into account your personal circumstances.

Please seek independent financial advice regarding your own situation, or if in doubt about the suitability of an investment.

Ryan Clarkson-Ledward

Ryan’s Premium Subscriptions

Publication logo
Fat Tail Investment Research

Latest Articles

  • America’s next Vietnam begins
    By Callum Newman

    I remember George W Bush on a US carrier declaring ‘Mission Accomplished’ when it came to Iraq in the second Gulf war. That was in 2003. The war was still going in 2011. Iraq became a failed state, instead of a flourishing democracy. The Iranians aren’t stupid.

  • Are we at war with China?
    By Nick Hubble

    Tariffs, fentanyl, the Straits of Hormuz, Canadian steel quotas and the EU admitting “Trump is right” all mean one thing: the West is finally taking on China.

  • Looking for the Catalyst: European Rearmament
    By James Cooper

    Every commodity cycle has a demand catalyst… James Cooper highlights one that few have paid attention to: conflict and military rearming. One of the primary drivers of higher metal prices. Read on to find out why this is important.

Primary Sidebar

Latest Articles

  • America’s next Vietnam begins
  • Are we at war with China?
  • Looking for the Catalyst: European Rearmament
  • An oil price spike is in the offing now
  • The Shopping Revolution No One Saw Coming

Footer

Fat Tail Daily Logo
YouTube
Facebook
x (formally twitter)
LinkedIn

About

Investment ideas from the edge of the bell curve.

Go beyond conventional investing strategies with unique ideas and actionable opportunities. Our expert editors deliver conviction-led insights to guide your financial journey.

Quick Links

Subscribe

About

FAQ

Terms and Conditions

Financial Services Guide

Privacy Policy

Get in Touch

Contact Us

Email: support@fattail.com.au

Phone: 1300 667 481

All advice is general in nature and has not taken into account your personal circumstances. Please seek independent financial advice regarding your own situation, or if in doubt about the suitability of an investment.

The value of any investment and the income derived from it can go down as well as up. Never invest more than you can afford to lose and keep in mind the ultimate risk is that you can lose whatever you’ve invested. While useful for detecting patterns, the past is not a guide to future performance. Some figures contained in our reports are forecasts and may not be a reliable indicator of future results. Any actual or potential gains in these reports may not include taxes, brokerage commissions, or associated fees.

Fat Tail Logo

Fat Tail Daily is brought to you by the team at Fat Tail Investment Research

Copyright © 2025 Fat Tail Daily | ACN: 117 765 009 / ABN: 33 117 765 009 / ASFL: 323 988